Rectus Sheath Hematoma in COVID-19: Clinical and Imaging Findings

What is it about?

The study discussing the occurrence of rectus sheath hematoma (RSH) in COVID-19 patients. The study observed 9,876 COVID-19 patients, out of which 12 (0.12%) were diagnosed with RSH. The majority of RSH cases were found in female patients, and the mean age of the RSH patients was 68.25 years. The study assessed laboratory values such as hemoglobin, hematocrit, d-dimer, and found that they were elevated at the time of presentation. The diagnosis of RSH was made using ultrasound (USG) and confirmed with computed tomography (CT). Treatment included anticoagulant therapy and, in severe cases, packed red blood cell replacement. The mortality rate among RSH patients was 25%. The study highlights the increased risk of RSH in COVID-19 patients, especially in those with risk factors such as female gender, advanced age, and elevated d-dimer levels. The importance of considering RSH in the differential diagnosis of acute abdominal pain or palpable abdominal masses in COVID-19 patients is emphasized, and USG is recommended as the initial imaging modality for diagnosis.

Featured Image

Photo by Andre Taissin on Unsplash

Photo by Andre Taissin on Unsplash

Why is it important?

This study is important because it highlights the increased occurrence of rectus sheath hematoma (RSH) in COVID-19 patients, particularly in those receiving anticoagulant treatment. RSH can be a potentially fatal complication, and its recognition is crucial for timely intervention. The study identifies risk factors such as female gender, advanced age, and elevated d-dimer levels associated with RSH in COVID-19 patients. It emphasizes the need for healthcare professionals to consider RSH in the differential diagnosis of acute abdominal pain or palpable masses in this population. The use of ultrasound as the initial imaging modality for diagnosis is also highlighted, facilitating prompt management and potentially reducing morbidity and mortality rates associated with RSH in COVID-19 patients.